Juan Vegarra · Company builder · Capital raiser · Author
Mining. High tech. Cybersecurity. Medical devices. Different industries, same discipline: find the large market, learn faster than the incumbents, and raise the capital to win it. Thirty five years and counting.
MICROSOFT → MINING → CAPITAL → CYBERSECURITY → MEDTECH + AI
Clearance is not adoption, and the proof sits in almost every cath lab in the country.
The hardest customer for AI is the professional who is not allowed to believe you.
Insiders inherit their industry's assumptions. Outsiders get to question them.
Usually the value already exists. What is missing is the institution around it.
The Thesis
Most companies do not stall because they lack technology, talent, or attractive markets. They stall because the organization never evolves as quickly as its opportunity. The answer is not optimizing yesterday's operating model. It is strengthening the enterprise itself. Boards have repeatedly trusted me at strategic inflection points, when the technology, the product, or the asset already existed, but the company needed to become a different organization before it could become a larger one. My work is building that institution. Strengthen the enterprise first. Then accelerate growth.
Built commercial operating discipline and expanded the regional business dramatically. The lesson that has held for three decades: growth is not a heroic act. It is a system, and systems can be built anywhere.
Founded, financed, and governed a public company. $500K seed to a $160M market cap. No geology degree. What I built instead was the institution around the asset: capital discipline, public-company governance, and a global investor base. The shareholders saw the result.
I left Microsoft for an Executive MBA at the UW Foster School of Business. A deliberate retooling. It gave me the financial toolkit to launch Vegarra Investments in 1999, and everything since flows from it: an active angel investor with strong portfolio returns, applying the same enterprise-building principles across new terrain. The portfolio did something the operating roles could not: it forced me deep into FinTech, telecom, real estate, and entertainment. Board decks, cap tables, and unit economics across eight industries. The model transferred. That was the point.
Today I serve as Chief Revenue Officer at VerAvanti, a MedTech company building the hardware-enabled AI platform for interventional imaging. The work: integrate capital strategy, commercialization, finance, and partnerships to prepare the company for institutional scale. The connection is personal. My father's bypass surgery taught me what cardiovascular medicine means to a family.
Founded Vena Resources. $500K seed to a $160M market cap.
Software infrastructure and platforms, operated across multiple countries.
Founded a fractional CISO practice for the mid-market. The lesson: the channel decides the market.
CRO at VerAvanti. Regulated markets, clinical evidence, capital intensity.
Early investor in a Peruvian FinTech. Exited to Experian.
Seed investor and board member in a broadband network into the Andes. Exited to a large foreign industrial group.
Asset-backed returns and the discipline of cash flow over story.
Hit-driven economics, where the audience is the moat and timing is the risk.
Four rules I have paid for. They are the spine of everything I build, and everything I advise on.
Insiders inherit their industry's assumptions. Outsiders get to question them. Every company I have built started with a question the incumbents stopped asking years ago.
Nobody buys a spec sheet. They buy what changes for them. If your differentiation cannot be stated as a customer outcome in one sentence, you do not have differentiation yet.
Raising money is not an interruption to building the company. It is part of building the company. The story, the model, and the investor must be chosen with the same rigor as the product.
Chocolate cake first. Lead with the answer, then earn it with the reasoning. Boards, investors, and customers all reward the person who respects their time.
A dataset is a snapshot that decays. A moat is a flywheel. The ninety-day test tells you which one you own.
The first commercial decision a MedTech company makes is buried in its 510(k) paperwork.
Prove the motion, then pour the capital. In that order, always.
Three clinical worlds, three definitions of better, one discipline that survives contact with all of them.
The Book
The generalist is not a compromise. The generalist is an edge. An Outsider's Playbook traces a career that runs from a Lima childhood to mining, software, and medical devices, and makes the case that the builders who matter most are the ones who arrive without permission.
It is a working book, not a memoir of anecdotes. Every chapter ends in something you can use: how to enter a technical industry you were not trained for, how to raise capital across borders, how to earn the trust of specialists without pretending to be one.
About the book Get notified at launchUsually the value already exists.
What is missing is the institution around it.
Most of my time goes to building. But a few times each year, I sit with a CEO or a board working through a hard question. Usually the value already exists. What is missing is the institution around it.
The question is usually one of three: a raise that has to land, a market the team did not come from, or a story that is not converting. These are the problems I have spent thirty five years inside, from both sides of the table. My record is value creation beyond operational optimization: strengthen the enterprise first, then accelerate growth.
The pattern has held across eight industries. MedTech, high tech, mining, and cybersecurity as an operator. FinTech, telecom, real estate, and entertainment as an investor. If you lead in any of them, we will not spend the first hour on vocabulary.
Investment firms use me the same way. A few venture and private equity partners treat me as an extension of their team: diligence in industries the fund did not come from, portfolio companies at inflection points, and capital stories that need to convert.
Some of this work I already do for free, by design. For the past three years I have served as a mentor in Ascend, the national network anchored at my alma mater, the UW Foster School of Business, and sponsored by JPMorgan Chase, working with CEOs of minority owned businesses scaling from $5M onward. My calling is simple. Scaling advice should not require seven figure consulting fees. After 35 years of learning, this is how I give back. And helping a founder cross from $5M to real scale is the most honest test of whether advice works.
If that sounds like your table, write me. If I cannot help, I will tell you quickly and, where I can, point you to someone who can.
Start a conversationThe Book · One Page
How Generalists Build Extraordinary Companies in Industries They Didn't Invent
The argument is simple. The generalist is not a compromise. The generalist is an edge. Every industry rewards the person who arrives without its assumptions, asks the questions insiders stopped asking, and pairs that fresh sight with old discipline: capital, customers, and a story that converts. And when the moment comes, the nerve to make the company a different organization before it becomes a larger one.
This book traces thirty five years of doing exactly that. A kid from Lima who landed at Microsoft and helped scale a worldwide channel program to roughly $1B. Who then founded Vena Resources with no geology degree and took it from a $500K seed to a $160M market cap. Now medical devices, where the stakes are measured in patients, not just returns. Along the way, more than $95M raised across three continents, and a portfolio that forced fluency in FinTech, telecom, real estate, and entertainment, with exits to buyers like Experian.
It is a working book, not a trophy case. Each chapter closes with something you can use on Monday: how to enter a technical industry you were not trained for, how to earn the trust of specialists without pretending to be one, how to raise capital across borders, how to sell outcomes instead of features, and how to lead with the conclusion so busy people say yes faster.
Who it is for. CEOs and founders scaling past their first market. Board members weighing a leader from outside the industry. Investors betting on operators. And any generalist who has been told to stay in their lane.
